Contact
searchSearch
HMP Global
Login

ALK Videos

Corey Langer, MD, Abramson Cancer Center
Videos
Treatment Selection for ALK-Positive Metastatic Non-Small Cell Lung Cancer
09/04/2025
Corey J. Langer, MD, FACP
Corey Langer, MD, presents a case demonstrating how liquid biopsy identified an ALK fusion and guided treatment with alectinib, resulting in durable disease control and preserved quality of life in an older patient with metastatic non-small...
Corey Langer, MD, presents a case demonstrating how liquid biopsy identified an ALK fusion and guided treatment with alectinib, resulting in durable disease control and preserved quality of life in an older patient with metastatic non-small...
Corey Langer, MD, presents a...
09/04/2025
Oncology
Videos
Researchers Demonstrate Promising Efficacy of Lorlatinib in Patients With ALK+ NSCLC
06/10/2020
David Carbone, MD, PhD, offers his perspective on 2 clinical trials that evaluated the use of lorlatinib in patients with ALK-positive NSCLC.
David Carbone, MD, PhD, offers his perspective on 2 clinical trials that evaluated the use of lorlatinib in patients with ALK-positive NSCLC.
David Carbone, MD, PhD, offers...
06/10/2020
Oncology
Videos
Alectinib Extends Survival in Treatment-Naïve Patients With ALK+ NSCLC
06/04/2020
Yasir Elamin, MD, discusses the findings of a study comparing alectinib with crizotinib in treatment-naïve patients with ALK-positive NSCLC.
Yasir Elamin, MD, discusses the findings of a study comparing alectinib with crizotinib in treatment-naïve patients with ALK-positive NSCLC.
Yasir Elamin, MD, discusses the...
06/04/2020
Oncology
Videos
NGS of Cell-Free Plasma DNA Shows Value in Management of Patients With ALK+ NSCLC
06/02/2020
David Carbone, MD, PhD, talks about the usefulness of NGS for cell-free plasma DNA in patients with ALK-positive NSCLC.
David Carbone, MD, PhD, talks about the usefulness of NGS for cell-free plasma DNA in patients with ALK-positive NSCLC.
David Carbone, MD, PhD, talks...
06/02/2020
Oncology
Videos
Anti–PD-L1 Therapy Not Recommended for Patients With NSCLC, Active Brain Metastases
06/01/2020
David Carbone, MD, PhD, comments on a study evaluating the efficacy of anti–PD1/PD-L1 monotherapy for patients with NSCLC and active brain metastases.
David Carbone, MD, PhD, comments on a study evaluating the efficacy of anti–PD1/PD-L1 monotherapy for patients with NSCLC and active brain metastases.
David Carbone, MD, PhD, comments...
06/01/2020
Oncology
Videos
Lorlatinib Shows Promise in Real-World Study of Patients With ALK+ NSCLC
06/01/2020
Yasir Elamin, MD, talks about how a study examining the real-world use of lorlatinib for ALK-positive NSCLC supports previously reported phase 2 trial data about this drug.
Yasir Elamin, MD, talks about how a study examining the real-world use of lorlatinib for ALK-positive NSCLC supports previously reported phase 2 trial data about this drug.
Yasir Elamin, MD, talks about...
06/01/2020
Oncology
Videos
Brigatinib Plus LCT Safe, Feasible for TKI-Naïve Patients With ALK+ NSCLC
05/31/2020
Yasir Elamin, MD, talks about the findings of a study in which LCT plus brigatinib was shown to be an effective treatment for ALK-rearranged advanced NSCLC.
Yasir Elamin, MD, talks about the findings of a study in which LCT plus brigatinib was shown to be an effective treatment for ALK-rearranged advanced NSCLC.
Yasir Elamin, MD, talks about...
05/31/2020
Oncology
Videos
Experts Identify Mutational Biomarker for Poor Prognosis in ALK+ NSCLC
05/30/2020
David Carbone, MD, PhD, comments on a study in which a mutation was identified as a biomarker for poor prognosis in patients with ALK-positive NSCLC.
David Carbone, MD, PhD, comments on a study in which a mutation was identified as a biomarker for poor prognosis in patients with ALK-positive NSCLC.
David Carbone, MD, PhD, comments...
05/30/2020
Oncology
Videos
Combining LCT and Brigatinib May Benefit Patients With ALK+ NSCLC
05/27/2020
David Carbone, MD, PhD, comments on a study evaluating the use of LCT plus brigatinib for patients with ALK-positive NSCLC.
David Carbone, MD, PhD, comments on a study evaluating the use of LCT plus brigatinib for patients with ALK-positive NSCLC.
David Carbone, MD, PhD, comments...
05/27/2020
Oncology

Recent News

News
Camrelizumab Plus Apatinib Demonstrates Encoruaging Activity in Patients With Refractory Chordoma
06/26/2026
Emily Estrada
According to results from an investigator-initiated phase 2 study, camrelizumab plus apatinib demonstrated encouraging efficacy and durable disease control in patients with refractory chordoma.
According to results from an investigator-initiated phase 2 study, camrelizumab plus apatinib demonstrated encouraging efficacy and durable disease control in patients with refractory chordoma.
According to results from an...
06/26/2026
Oncology
News
Ten-Year Follow-Up Supports Curative Potential of Tisagenlecleucel in Patients With B-Cell Non-Hodgkin Lymphomas
06/25/2026
Stephanie Holland
Long-term follow-up of patients with relapsed or refractory B-cell non-Hodgkin lymphoma demonstrated that tisagenlecleucel induced durable remissions, with no disease relapses occurring beyond 5.4 years after treatment.
Long-term follow-up of patients with relapsed or refractory B-cell non-Hodgkin lymphoma demonstrated that tisagenlecleucel induced durable remissions, with no disease relapses occurring beyond 5.4 years after treatment.
Long-term follow-up of patients...
06/25/2026
Oncology
News
Pirtobrutinib Demonstrates Durable Clinical Activity in Relapsed or Refractory Waldenström Macroglobulinemia
06/25/2026
Stephanie Holland
Results from the phase 1/2 BRUIN trial demonstrated that pirtobrutinib shows durable clinical activity in relapsed or refractory Waldenström macroglobulinemia, including those previously treated with covalent Bruton tyrosine kinase inhibitors.
Results from the phase 1/2 BRUIN trial demonstrated that pirtobrutinib shows durable clinical activity in relapsed or refractory Waldenström macroglobulinemia, including those previously treated with covalent Bruton tyrosine kinase inhibitors.
Results from the phase 1/2 BRUIN...
06/25/2026
Oncology
News
Nivolumab Plus Ipilimumab Shows Encouraging Activity in Advanced Gallbladder Carcinoma
06/25/2026
Stephanie Holland
According to results from the phase 2 MoST-CIRCUIT trial, nivolumab plus ipilimumab demonstrated encouraging activity in patients with gallbladder carcinoma despite limited overall efficacy in patients with advanced biliary tract cancers.
According to results from the phase 2 MoST-CIRCUIT trial, nivolumab plus ipilimumab demonstrated encouraging activity in patients with gallbladder carcinoma despite limited overall efficacy in patients with advanced biliary tract cancers.
According to results from the...
06/25/2026
Oncology
News
Neoadjuvant Nivolumab Demonstrates Strong Activity in Resectable Mismatch Repair-Deficient Endometrial Cancer
06/23/2026
Emily Estrada
Results from a phase 2 study demonstrated that neoadjuvant nivolumab induced high rates of complete response among patients with resectable mismatch repair-deficient endometrial cancer.
Results from a phase 2 study demonstrated that neoadjuvant nivolumab induced high rates of complete response among patients with resectable mismatch repair-deficient endometrial cancer.
Results from a phase 2 study...
06/23/2026
Oncology
News
Bulumtatug Fuvedotin Demonstrates Durable Activity in Previously Treated Cervical Cancer
06/23/2026
Emily Estrada
Updated results from a phase 2 study demonstrated that bulumtatug fuvedotin shows encouraging efficacy and manageable tolerability in patients with recurrent or metastatic cervical cancer, including those previously treated with immune...
Updated results from a phase 2 study demonstrated that bulumtatug fuvedotin shows encouraging efficacy and manageable tolerability in patients with recurrent or metastatic cervical cancer, including those previously treated with immune...
Updated results from a phase 2...
06/23/2026
Oncology
FDA Approval
FDA Approves Afamitresgene Autoleucel for Patients With Unresectable or Metastatic Synovial Sarcoma
06/23/2026
Stephanie Holland
Based on results from the SPEARHEAD-1 study, the FDA granted full approval to afamitresgene autoleucel for unresectable or metastatic synovial sarcoma and expanded its indication to include eligible patients aged 12 years and older.
Based on results from the SPEARHEAD-1 study, the FDA granted full approval to afamitresgene autoleucel for unresectable or metastatic synovial sarcoma and expanded its indication to include eligible patients aged 12 years and older.
Based on results from the...
06/23/2026
Oncology
News
Signatera-Based ctDNA Testing Incorporated Into NCCN Bladder Cancer Guidelines
06/23/2026
Stephanie Holland
The NCCN has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer to include tumor-informed ctDNA-MRD testing as a tool for risk stratification and treatment selection in patients with muscle-invasive bladder cancer.
The NCCN has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer to include tumor-informed ctDNA-MRD testing as a tool for risk stratification and treatment selection in patients with muscle-invasive bladder cancer.
The NCCN has updated its...
06/23/2026
Oncology
News
Dostarlimab Demonstrates Durable 6-Year Survival Benefit in dMMR/MSI-H Endometrial Cancer
06/18/2026
Stephanie Holland
Updated results from the phase 1 GARNET trial demonstrated durable long-term clinical benefit with dostarlimab monotherapy in patients with dMMR/MSI-H advanced or recurrent endometrial cancer.
Updated results from the phase 1 GARNET trial demonstrated durable long-term clinical benefit with dostarlimab monotherapy in patients with dMMR/MSI-H advanced or recurrent endometrial cancer.
Updated results from the phase 1...
06/18/2026
Oncology
News
Updated Results from the RUBY Trial Reinforce Dostarlimab as Standard of Care in dMMR/MSI-H Endometrial Cancer
06/18/2026
Stephanie Holland
Updated results from the phase 3 RUBY trial demonstrated that dostarlimab plus carboplatin and paclitaxel sustained survival benefit in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
Updated results from the phase 3 RUBY trial demonstrated that dostarlimab plus carboplatin and paclitaxel sustained survival benefit in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.
Updated results from the phase 3...
06/18/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use